425 related articles for article (PubMed ID: 31547603)
1. The Role of Molecular Testing for the Indeterminate Thyroid FNA.
Rossi ED; Pantanowitz L; Faquin WC
Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31547603
[TBL] [Abstract][Full Text] [Related]
2. Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology.
Nikiforov YE; Carty SE; Chiosea SI; Coyne C; Duvvuri U; Ferris RL; Gooding WE; LeBeau SO; Ohori NP; Seethala RR; Tublin ME; Yip L; Nikiforova MN
Thyroid; 2015 Nov; 25(11):1217-23. PubMed ID: 26356635
[TBL] [Abstract][Full Text] [Related]
3. Preoperative detection of malignancy in fine-needle aspiration cytology (FNAC) smears with indeterminate cytology (Bethesda III, IV) by a combined molecular classifier.
Titov S; Demenkov PS; Lukyanov SA; Sergiyko SV; Katanyan GA; Veryaskina YA; Ivanov MK
J Clin Pathol; 2020 Nov; 73(11):722-727. PubMed ID: 32213552
[TBL] [Abstract][Full Text] [Related]
4. Centrifuged supernatants from FNA provide a liquid biopsy option for clinical next-generation sequencing of thyroid nodules.
Ye W; Hannigan B; Zalles S; Mehrotra M; Barkoh BA; Williams MD; Cabanillas ME; Edeiken-Monroe B; Hu P; Duose D; Wistuba II; Medeiros LJ; Stewart J; Luthra R; Roy-Chowdhuri S
Cancer Cytopathol; 2019 Mar; 127(3):146-160. PubMed ID: 30620446
[TBL] [Abstract][Full Text] [Related]
5. A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration.
Keutgen XM; Filicori F; Crowley MJ; Wang Y; Scognamiglio T; Hoda R; Buitrago D; Cooper D; Zeiger MA; Zarnegar R; Elemento O; Fahey TJ
Clin Cancer Res; 2012 Apr; 18(7):2032-8. PubMed ID: 22351693
[TBL] [Abstract][Full Text] [Related]
6. Thyroid cytology smear slides: An untapped resource for ThyroSeq testing.
Nikiforova MN; Lepe M; Tolino LA; Miller ME; Ohori NP; Wald AI; Landau MS; Kaya C; Malapelle U; Bellevicine C; Troncone G; Nikiforov YE; Baloch Z
Cancer Cytopathol; 2021 Jan; 129(1):33-42. PubMed ID: 32697051
[TBL] [Abstract][Full Text] [Related]
7. Utility of a multigene testing for preoperative evaluation of indeterminate thyroid nodules: A prospective blinded single center study in China.
Song Y; Xu G; Ma T; Zhu Y; Yu H; Yu W; Wei W; Wang T; Zhang B
Cancer Med; 2020 Nov; 9(22):8397-8405. PubMed ID: 32976686
[TBL] [Abstract][Full Text] [Related]
8. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
Witt RL
Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
[TBL] [Abstract][Full Text] [Related]
9. The mutational analysis in the diagnostic work-up of thyroid nodules: the real impact in a center with large experience in thyroid cytopathology.
Macerola E; Rago T; Proietti A; Basolo F; Vitti P
J Endocrinol Invest; 2019 Feb; 42(2):157-166. PubMed ID: 29704233
[TBL] [Abstract][Full Text] [Related]
10. [Next generation sequencing].
Le Mercier M; D'Haene N; Rorive S; Degand C; De Nève N; Blanchard O; Salmon I
Rev Med Brux; 2016; 37(5):436-438. PubMed ID: 28525213
[TBL] [Abstract][Full Text] [Related]
11. Molecular testing in diagnosis of indeterminate thyroid cytology: Trends and drivers.
Kumar N; Gupta R; Gupta S
Diagn Cytopathol; 2020 Nov; 48(11):1144-1151. PubMed ID: 32501611
[TBL] [Abstract][Full Text] [Related]
12. Triage of the indeterminate thyroid aspirate: What are the options for the practicing cytopathologist?
Onenerk AM; Pusztaszeri MP; Canberk S; Faquin WC
Cancer Cytopathol; 2017 Jun; 125(S6):477-485. PubMed ID: 28609009
[TBL] [Abstract][Full Text] [Related]
13. BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance.
Adeniran AJ; Hui P; Chhieng DC; Prasad ML; Schofield K; Theoharis C
Acta Cytol; 2011; 55(6):570-5. PubMed ID: 22156468
[TBL] [Abstract][Full Text] [Related]
14. Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules.
Nikiforova MN; Mercurio S; Wald AI; Barbi de Moura M; Callenberg K; Santana-Santos L; Gooding WE; Yip L; Ferris RL; Nikiforov YE
Cancer; 2018 Apr; 124(8):1682-1690. PubMed ID: 29345728
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic biomarkers of differentiated thyroid cancer.
Kunavisarut T
Endocrine; 2013 Dec; 44(3):616-22. PubMed ID: 23645523
[TBL] [Abstract][Full Text] [Related]
16. Molecular analysis of residual ThinPrep material from thyroid FNAs increases diagnostic sensitivity.
Krane JF; Cibas ES; Alexander EK; Paschke R; Eszlinger M
Cancer Cytopathol; 2015 Jun; 123(6):356-61. PubMed ID: 25926393
[TBL] [Abstract][Full Text] [Related]
17. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes.
Baca SC; Wong KS; Strickland KC; Heller HT; Kim MI; Barletta JA; Cibas ES; Krane JF; Marqusee E; Angell TE
Cancer Cytopathol; 2017 May; 125(5):313-322. PubMed ID: 28152275
[TBL] [Abstract][Full Text] [Related]
18. Role of Ancillary Techniques in Thyroid Cytology Specimens.
Nishino M; Krane JF
Acta Cytol; 2020; 64(1-2):40-51. PubMed ID: 30947167
[TBL] [Abstract][Full Text] [Related]
19. A large multicenter correlation study of thyroid nodule cytopathology and histopathology.
Wang CC; Friedman L; Kennedy GC; Wang H; Kebebew E; Steward DL; Zeiger MA; Westra WH; Wang Y; Khanafshar E; Fellegara G; Rosai J; Livolsi V; Lanman RB
Thyroid; 2011 Mar; 21(3):243-51. PubMed ID: 21190442
[TBL] [Abstract][Full Text] [Related]
20. Young investigator challenge: Can the Ion AmpliSeq Cancer Hotspot Panel v2 be used for next-generation sequencing of thyroid FNA samples?
Bellevicine C; Sgariglia R; Malapelle U; Vigliar E; Nacchio M; Ciancia G; Eszlinger M; Paschke R; Troncone G
Cancer Cytopathol; 2016 Nov; 124(11):776-784. PubMed ID: 27717198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
